NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts have an average rating of "Hold" on NeoGenomics from 14 brokerages (1 sell, 8 hold, 5 buy) with a 12‑month average price target of about $11.86.
• COO Warren Stone sold 22,128 shares at $12.50 on Jan. 20, reducing his stake by 15.39%; insiders now own 2.40% of the company while institutions own 98.5%.
• NeoGenomics beat the quarter with EPS $0.06 vs. $0.04 expected and revenue $190.17M (+10.6% YoY), but the company still shows a negative net margin (‑14.85%) and analysts project about ‑$0.20 EPS for the current fiscal year.

Shares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) have been assigned an average rating of "Hold" from the fourteen brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $11.8571.

A number of brokerages have weighed in on NEO. UBS Group reaffirmed a "hold" rating on shares of NeoGenomics in a research report on Wednesday, February 18th. Zacks Research lowered shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 20th. Needham & Company LLC lifted their target price on shares of NeoGenomics from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Piper Sandler lifted their price target on NeoGenomics from $12.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 24th. Finally, William Blair restated a "market perform" rating on shares of NeoGenomics in a report on Monday.

Insider Transactions at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares in the company, valued at $1,520,387.50. This trade represents a 15.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by company insiders.

Institutional Trading of NeoGenomics

Large investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd raised its position in shares of NeoGenomics by 42.5% during the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company's stock worth $26,000 after acquiring an additional 997 shares during the last quarter. First Horizon Corp boosted its position in shares of NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company's stock worth $30,000 after purchasing an additional 865 shares during the last quarter. Headlands Technologies LLC bought a new stake in NeoGenomics in the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd increased its holdings in NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company's stock valued at $35,000 after purchasing an additional 1,556 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in NeoGenomics in the fourth quarter valued at about $39,000. 98.50% of the stock is owned by institutional investors.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $8.18 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.94 and a debt-to-equity ratio of 0.41. NeoGenomics has a 1 year low of $4.72 and a 1 year high of $13.74. The business has a fifty day simple moving average of $10.85 and a 200 day simple moving average of $10.48. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -9.74 and a beta of 1.62.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.02. The firm had revenue of $190.17 million during the quarter, compared to analysts' expectations of $188.25 million. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The business's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.04 earnings per share. As a group, sell-side analysts predict that NeoGenomics will post -0.2 earnings per share for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company's core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.